Exposure-Response Analyses to Support Ph3 Dose Selection for I-Dxd (ifinatamab Deruxtecan) in Extensive Stage SCLC Patients

N. M. Midde, S. Hennig, B. P. Tran,M. Qian, M. Tang, J. Singh, S. S. Vaidya, Y. Lau

JOURNAL OF THORACIC ONCOLOGY（2024）

Cited 0|Views0

Key words

ER analysis,SCLC,antibody drug conjugate

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined